{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:14:39Z","timestamp":1787066079069,"version":"build-2736575974"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s40265-023-01841-4","type":"journal-article","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T23:02:50Z","timestamp":1679353370000},"page":"403-427","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7895-198X","authenticated-orcid":false,"given":"Joseph E.","family":"Blais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5213-7664","authenticated-orcid":false,"given":"Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1564-0057","authenticated-orcid":false,"given":"Jie V.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,21]]},"reference":[{"issue":"18","key":"1841_CR1","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41569-021-00541-410.1038\/s41569-021-00541-4","volume":"8","author":"A Pirillo","year":"2021","unstructured":"Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global epidemiology of dyslipidaemias. Nat Rev Cardiol. 2021;8(18):689\u2013700. https:\/\/doi.org\/10.1038\/s41569-021-00541-410.1038\/s41569-021-00541-4.","journal-title":"Nat Rev Cardiol"},{"issue":"7810","key":"1841_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41586-020-2338-1","volume":"582","author":"N. C. D. Risk Factor Collaboration","year":"2020","unstructured":"N. C. D. Risk Factor Collaboration. Repositioning of the global epicentre of non-optimal cholesterol. Nature. 2020;582(7810):73\u20137. https:\/\/doi.org\/10.1038\/s41586-020-2338-1.","journal-title":"Nature"},{"key":"1841_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2021.05.016","volume":"328","author":"JE Blais","year":"2021","unstructured":"Blais JE, Wei Y, Yap KKW, Alwafi H, Ma TT, Brauer R, et al. Trends in lipid-modifying agent use in 83 countries. Atherosclerosis. 2021;328:44\u201351. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.05.016.","journal-title":"Atherosclerosis"},{"issue":"34","key":"1841_CR4","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","volume":"43","author":"I Bytyci","year":"2022","unstructured":"Bytyci I, Penson PE, Mikhailidis DP, Wong ND, Hernandez AV, Sahebkar A, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;43(34):3213\u201323. https:\/\/doi.org\/10.1093\/eurheartj\/ehac015.","journal-title":"Eur Heart J"},{"key":"1841_CR5","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ejphar.2015.05.068","volume":"761","author":"AE Kumar","year":"2015","unstructured":"Kumar AE, Chopra K, Mukherjee M, Pottabathini R, Dhull DK. Current knowledge and pharmacological profile of berberine: an update. Eur J Pharmacol. 2015;761:288\u201397. https:\/\/doi.org\/10.1016\/j.ejphar.2015.05.068.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"1841_CR6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.atherosclerosis.2015.09.032","volume":"243","author":"A Pirillo","year":"2015","unstructured":"Pirillo A, Catapano AL. Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies. Atherosclerosis. 2015;243(2):449\u201361. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.09.032.","journal-title":"Atherosclerosis"},{"issue":"5","key":"1841_CR7","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s11684-019-0724-6","volume":"14","author":"D Song","year":"2020","unstructured":"Song D, Hao J, Fan D. Biological properties and clinical applications of berberine. Front Med. 2020;14(5):564\u201382. https:\/\/doi.org\/10.1007\/s11684-019-0724-6.","journal-title":"Front Med"},{"issue":"1","key":"1841_CR8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jacc.2018.04.040","volume":"72","author":"M Banach","year":"2018","unstructured":"Banach M, Patti AM, Giglio RV, Cicero AFG, Atanasov AG, Bajraktari G, et al. The role of nutraceuticals in statin\u00a0intolerant patients. J Am Coll Cardiol. 2018;72(1):96\u2013118. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.040.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1841_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"issue":"6","key":"1841_CR10","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1055\/s-0032-1328321","volume":"79","author":"H Dong","year":"2013","unstructured":"Dong H, Zhao Y, Zhao L, Lu F. The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials. Planta Med. 2013;79(6):437\u201346. https:\/\/doi.org\/10.1055\/s-0032-1328321.","journal-title":"Planta Med"},{"key":"1841_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jep.2014.09.049","volume":"161","author":"J Lan","year":"2015","unstructured":"Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015;161:69\u201381. https:\/\/doi.org\/10.1016\/j.jep.2014.09.049.","journal-title":"J Ethnopharmacol"},{"issue":"4","key":"1841_CR12","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1177\/2156587216687695","volume":"22","author":"LM Koppen","year":"2017","unstructured":"Koppen LM, Whitaker A, Rosene A, Beckett RD. Efficacy of berberine alone and in combination for the treatment of hyperlipidemia: a systematic review. J Evid-Based Complement Altern Med. 2017;22(4):956\u201368. https:\/\/doi.org\/10.1177\/2156587216687695.","journal-title":"J Evid-Based Complement Altern Med"},{"key":"1841_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.phymed.2018.09.212","volume":"50","author":"J Ju","year":"2018","unstructured":"Ju J, Li J, Lin Q, Xu H. Efficacy and safety of berberine for dyslipidaemias: a systematic review and meta-analysis of randomized clinical trials. Phytomedicine. 2018;50:25\u201334. https:\/\/doi.org\/10.1016\/j.phymed.2018.09.212.","journal-title":"Phytomedicine"},{"issue":"04","key":"1841_CR14","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1142\/s0192415x19500393","volume":"47","author":"L-S Zhang","year":"2019","unstructured":"Zhang L-S, Zhang J-H, Feng R, Jin X-Y, Yang F-W, Ji Z-C, et al. Efficacy and safety of berberine alone or combined with statins for the treatment of hyperlipidemia: a systematic review and meta-analysis of randomized controlled clinical trials. Am J Chin Med. 2019;47(04):751\u201367. https:\/\/doi.org\/10.1142\/s0192415x19500393.","journal-title":"Am J Chin Med"},{"issue":"4","key":"1841_CR15","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/ptr.6282","volume":"33","author":"F Fogacci","year":"2019","unstructured":"Fogacci F, Grassi D, Rizzo M, Cicero AFG. Metabolic effect of berberine\u2013silymarin association: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Phytother Res. 2019;33(4):862\u201370. https:\/\/doi.org\/10.1002\/ptr.6282.","journal-title":"Phytother Res"},{"issue":"2","key":"1841_CR16","doi-asserted-by":"publisher","first-page":"638","DOI":"10.3390\/nu13020638","volume":"13","author":"AFG Cicero","year":"2021","unstructured":"Cicero AFG, Kennedy C, Kne\u017eevi\u0107 T, Bove M, Georges CMG, \u0160atrauskien\u0117 A, et al. Efficacy and safety of Armolipid Plus\u00ae: an updated prisma compliant systematic review and meta-analysis of randomized controlled clinical trials. Nutrients. 2021;13(2):638. https:\/\/doi.org\/10.3390\/nu13020638.","journal-title":"Nutrients"},{"key":"1841_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.653887","author":"Y Ye","year":"2021","unstructured":"Ye Y, Liu X, Wu N, Han Y, Wang J, Yu Y, et al. Efficacy and safety of berberine alone for several metabolic disorders: a systematic review and meta-analysis of randomized clinical trials. Front Pharmacol. 2021. https:\/\/doi.org\/10.3389\/fphar.2021.653887.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1841_CR18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.numecd.2016.11.122","volume":"27","author":"M Pirro","year":"2017","unstructured":"Pirro M, Vetrani C, Bianchi C, Mannarino MR, Bernini F, Rivellese AA. Joint position statement on \u201cNutraceuticals for the treatment of hypercholesterolemia\u201d of the Italian Society of Diabetology (SID) and of the Italian Society for the Study of Arteriosclerosis (SISA). Nutr Metab Cardiovasc Dis. 2017;27(1):2\u201317. https:\/\/doi.org\/10.1016\/j.numecd.2016.11.122.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"3","key":"1841_CR19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/19390211.2017.1347227","volume":"15","author":"RS Funk","year":"2018","unstructured":"Funk RS, Singh RK, Winefield RD, Kandel SE, Ruisinger JF, Moriarty PM, et al. Variability in potency among commercial preparations of berberine. J Diet Suppl. 2018;15(3):343\u201351. https:\/\/doi.org\/10.1080\/19390211.2017.1347227.","journal-title":"J Diet Suppl"},{"issue":"8","key":"1841_CR20","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.3390\/molecules26082222","volume":"26","author":"S Marcheluzzo","year":"2021","unstructured":"Marcheluzzo S, Faggian M, Zancato M, Peron G. Analysis of monacolins and berberine in food supplements for lipid control: an overview of products sold on the Italian market. Molecules. 2021;26(8):2222. https:\/\/doi.org\/10.3390\/molecules26082222","journal-title":"Molecules"},{"key":"1841_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.7554\/eLife.58567","volume":"25","author":"CM Schooling","year":"2020","unstructured":"Schooling CM, Zhao JV, Au Yeung SL, Leung GM. Investigating pleiotropic effects of statins on ischemic heart disease in the UK Biobank using Mendelian randomisation. Elife. 2020;25:9. https:\/\/doi.org\/10.7554\/eLife.58567.","journal-title":"Elife"},{"issue":"8","key":"1841_CR22","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.3390\/nu13082550","volume":"13","author":"JV Zhao","year":"2021","unstructured":"Zhao JV, Yeung WF, Chan YH, Vackova D, Leung JYY, Ip DKM, et al. Effect of berberine on cardiovascular disease risk factors: a mechanistic randomized controlled trial. Nutrients. 2021;13(8):2550. https:\/\/doi.org\/10.3390\/nu13082550.","journal-title":"Nutrients"},{"issue":"1","key":"1841_CR23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1530\/eje-11-0616","volume":"166","author":"W Wei","year":"2012","unstructured":"Wei W, Zhao H, Wang A, Sui M, Liang K, Deng H, et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol. 2012;166(1):99\u2013105. https:\/\/doi.org\/10.1530\/eje-11-0616.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1841_CR24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/cen.12294","volume":"80","author":"Y An","year":"2014","unstructured":"An Y, Sun Z, Zhang Y, Liu B, Guan Y, Lu M. The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clin Endocrinol (Oxf). 2014;80(3):425\u201331. https:\/\/doi.org\/10.1111\/cen.12294.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"1841_CR25","doi-asserted-by":"publisher","first-page":"606","DOI":"10.3390\/nu14030606","volume":"14","author":"M Casula","year":"2022","unstructured":"Casula M, Catapano AL, Magni P. Nutraceuticals for dyslipidaemia and glucometabolic diseases: what the guidelines tell us (and Do Not Tell, Yet). Nutrients. 2022;14(3):606. https:\/\/doi.org\/10.3390\/nu14030606.","journal-title":"Nutrients"},{"key":"1841_CR26","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1841_CR27","doi-asserted-by":"publisher","first-page":"I4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:I4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"issue":"1","key":"1841_CR28","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.1038\/s41467-020-18414-8","volume":"11","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Gu Y, Ren H, Wang S, Zhong H, Zhao X, et al. Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). Nat Commun. 2020;11(1):5015. https:\/\/doi.org\/10.1038\/s41467-020-18414-8.","journal-title":"Nat Commun"},{"issue":"1","key":"1841_CR29","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13073-021-00942-7","volume":"13","author":"J Ming","year":"2021","unstructured":"Ming J, Yu X, Xu X, Wang L, Ding C, Wang Z, et al. Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a multi-center, double-blind, randomized, parallel-controlled study. Genome Med. 2021;13(1):125. https:\/\/doi.org\/10.1186\/s13073-021-00942-7.","journal-title":"Genome Med."},{"issue":"6","key":"1841_CR30","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","volume":"27","author":"D Luo","year":"2018","unstructured":"Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785\u2013805. https:\/\/doi.org\/10.1177\/0962280216669183.","journal-title":"Stat Methods Med Res"},{"issue":"14","key":"1841_CR31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"19","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;19(14):135. https:\/\/doi.org\/10.1186\/1471-2288-14-135.","journal-title":"BMC Med Res Methodol"},{"key":"1841_CR32","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A (editors). GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. https:\/\/guidelinedevelopment.org\/handbook. Accessed 15 Jan 2023."},{"key":"1841_CR33","unstructured":"McMaster University and Evidence Prime. GRADEpro GDT: GRADEpro Guideline Development Tool. [Software] 2022. https:\/\/gradepro.org. Accessed 15 Jan 2023."},{"issue":"10","key":"1841_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3969\/j.issn.0253-9896.2012.10.013","volume":"40","author":"H Deng","year":"2012","unstructured":"Deng H, Wei W, Guan Y. The clinical study of berberine in patients with polycystic ovarian syndrome and insulin resistance (Chinese). Tianjin Med J. 2012;40(10):3. https:\/\/doi.org\/10.3969\/j.issn.0253-9896.2012.10.013.","journal-title":"Tianjin Med J"},{"key":"1841_CR35","doi-asserted-by":"publisher","DOI":"10.16386\/j.cjpccd.issn.1004-6194.2016.04.007","author":"M Li","year":"2016","unstructured":"Li M, Li J, Liu Y, Zhao Y, Qiu Y, Jia Q, et al. The influence of berberine hydrochloride on glucolipid metabolism of patients with schizophrenia (Chinese). Chin J Prev Control Chronic Dis. 2016. https:\/\/doi.org\/10.16386\/j.cjpccd.issn.1004-6194.2016.04.007.","journal-title":"Chin J Prev Control Chronic Dis"},{"key":"1841_CR36","doi-asserted-by":"publisher","first-page":"113899","DOI":"10.1016\/j.psychres.2021.113899","volume":"300","author":"M Li","year":"2021","unstructured":"Li M, Liu Y, Qiu Y, Zhang J, Zhang Y, Zhao Y, et al. The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial. Psychiatry Res. 2021;300:113899. https:\/\/doi.org\/10.1016\/j.psychres.2021.113899.","journal-title":"Psychiatry Res"},{"issue":"5","key":"1841_CR37","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3969\/j.issn.1008-8849.2016.05.002","volume":"25","author":"Y An","year":"2016","unstructured":"An Y, Zhang Y, Lyu H, Li L, Sun Z. Effect of berberine on clinical, metabolic and endocrine index and pregnancy outcome in women with polycystic ovary syndrome undergoing IVF treatment (Chinese). Mod J Integr Tradit Chin Western Med. 2016;25(5):5. https:\/\/doi.org\/10.3969\/j.issn.1008-8849.2016.05.002.","journal-title":"Mod J Integr Tradit Chin Western Med"},{"issue":"12","key":"1841_CR38","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/nm1135","volume":"10","author":"W Kong","year":"2004","unstructured":"Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10(12):1344\u201351. https:\/\/doi.org\/10.1038\/nm1135.","journal-title":"Nat Med"},{"issue":"7","key":"1841_CR39","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1210\/jc.2007-2404","volume":"93","author":"Y Zhang","year":"2008","unstructured":"Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008;93(7):2559\u201365. https:\/\/doi.org\/10.1210\/jc.2007-2404.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1841_CR40","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1517\/14712598.2013.776037","volume":"13","author":"G Derosa","year":"2013","unstructured":"Derosa G, D\u2019Angelo A, Bonaventura A, Bianchi L, Romano D, Maffioli P. Effects of berberine on lipid profile in subjects with low cardiovascular risk. Expert Opin Biol Ther. 2013;13(4):475\u201382. https:\/\/doi.org\/10.1517\/14712598.2013.776037.","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"1841_CR41","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1089\/met.2012.0183","volume":"11","author":"KG P\u00e9rez-Rubio","year":"2013","unstructured":"P\u00e9rez-Rubio KG, Gonz\u00e1lez-Ortiz M, Mart\u00ednez-Abundis E, Robles-Cervantes JA, Espinel-Berm\u00fadez MC. Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord. 2013;11(5):366\u20139. https:\/\/doi.org\/10.1089\/met.2012.0183.","journal-title":"Metab Syndr Relat Disord"},{"issue":"6","key":"1841_CR42","doi-asserted-by":"publisher","first-page":"681","DOI":"10.7661\/CJIM.2016.06.0681","volume":"36","author":"L Wang","year":"2016","unstructured":"Wang L, Peng LY, Wei GH, Ge H. Therapeutic effects of berberine capsule on patients with mild hyperlipidemia (Chinese). Chin J Integr Tradit Western Med. 2016;36(6):681\u20134. https:\/\/doi.org\/10.7661\/CJIM.2016.06.0681.","journal-title":"Chin J Integr Tradit Western Med"},{"issue":"4","key":"1841_CR43","first-page":"338","volume":"22","author":"J Zhang","year":"2016","unstructured":"Zhang J, Zhao Y, Jia Q, Liu Y, Li M, Li J, et al. Effect of berberine on symptoms and glycolipid metabolism in schizophrenia patients treated with risperidone (Chinese). J Tianjin Med Univ. 2016;22(4):338\u201340. (CNKI:SUN:TJYK.0.2016-04-020).","journal-title":"J Tianjin Med Univ"},{"issue":"6","key":"1841_CR44","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3760\/cma.j.issn.1008-6706.2016.06.010","volume":"23","author":"Q Zhu","year":"2016","unstructured":"Zhu Q, Hu W, Dai C. Effects of berberine combined with ethinylestradiol cyproterone acetate in the treatment of obese women with polycystic ovary syndrome (Chinese). Chin J Prim Med cine and Pharm. 2016;23(6):837\u201340. https:\/\/doi.org\/10.3760\/cma.j.issn.1008-6706.2016.06.010.","journal-title":"Chin J Prim Med cine and Pharm"},{"issue":"S1","key":"1841_CR45","doi-asserted-by":"publisher","first-page":"125","DOI":"10.16440\/j.cnki.1674-8166.2018.s1.069","volume":"19","author":"Y Li","year":"2018","unstructured":"Li Y, Lin Y, Wang X, Wang H, Fan Y, Zhang H. Effect of berberine on blood glucose, lipids and insulin resistance in patients with polycystic ovary syndrome (Chinese). Chronic Pathematol J. 2018;19(S1):125\u20136. https:\/\/doi.org\/10.16440\/j.cnki.1674-8166.2018.s1.069.","journal-title":"Chronic Pathematol J"},{"issue":"1","key":"1841_CR46","doi-asserted-by":"publisher","first-page":"e64180","DOI":"10.5812\/jjnpp.64180","volume":"13","author":"H Rashidi","year":"2018","unstructured":"Rashidi H, Namjoyan F, Mehraban Z, Zakerkish M, Ghaderian SB, Latifi SM. The effects of active ingredients of barberry root (berberine) on glycemic control and insulin resistance in type 2 diabetic patients. Jundishapur J Nat Pharm Prod. 2018;13(1):e64180. https:\/\/doi.org\/10.5812\/jjnpp.64180.","journal-title":"Jundishapur J Nat Pharm Prod"},{"issue":"21","key":"1841_CR47","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.12056\/j.issn.1006-2785.2021.43.21.2020-3326","volume":"43","author":"J Hu","year":"2021","unstructured":"Hu J, Hu T, Wang J, Yu J, Wang J, Zhang Q. Effect of berberine combined with metformin on body fat distribution and liver fat content in type 2 diabetic patients with NAFLD (Chinese). Zhejiang Med. 2021;43(21):2327\u201331. https:\/\/doi.org\/10.12056\/j.issn.1006-2785.2021.43.21.2020-3326.","journal-title":"Zhejiang Med."},{"issue":"8","key":"1841_CR48","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1142\/S0192415X21500920","volume":"49","author":"Z Pu","year":"2021","unstructured":"Pu Z, Sun Y, Jiang H, Hou Q, Yan H, Wen H, et al. Effects of berberine on gut microbiota in patients with mild metabolic disorders induced by olanzapine. Am J Chin Med. 2021;49(8):1949\u201363. https:\/\/doi.org\/10.1142\/S0192415X21500920.","journal-title":"Am J Chin Med"},{"issue":"3","key":"1841_CR49","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/pcn.13323","volume":"76","author":"M Chan","year":"2022","unstructured":"Chan M, Qin Z, Man SC, Lam M, Lai WH, Ng RMK, et al. Adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial. Psychiatry Clin Neurosci. 2022;76(3):77\u201385. https:\/\/doi.org\/10.1111\/pcn.13323.","journal-title":"Psychiatry Clin Neurosci"},{"key":"1841_CR50","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ctim.2019.01.017","volume":"43","author":"A Hadi","year":"2019","unstructured":"Hadi A, Arab A, Ghaedi E, Rafie N, Miraghajani M, Kafeshani M. Barberry (Berberis vulgaris L.) is a safe approach for management of lipid parameters: a systematic review and meta-analysis of randomized controlled trials. Complement Therap Med. 2019;43:117\u201324. https:\/\/doi.org\/10.1016\/j.ctim.2019.01.017.","journal-title":"Complement Therap Med"},{"issue":"1","key":"1841_CR51","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/ije\/dyt239","volume":"43","author":"J Zhao","year":"2014","unstructured":"Zhao J, Jiang C, Lam TH, Liu B, Cheng KK, Xu L, et al. Genetically predicted testosterone and cardiovascular risk factors in men: a Mendelian randomization analysis in the Guangzhou Biobank Cohort Study. Int J Epidemiol. 2014;43(1):140\u20138. https:\/\/doi.org\/10.1093\/ije\/dyt239.","journal-title":"Int J Epidemiol"},{"issue":"6","key":"1841_CR52","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1210\/jc.2009-2575","volume":"95","author":"MM Fern\u00e1ndez-Balsells","year":"2010","unstructured":"Fern\u00e1ndez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, et al. Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560\u201375. https:\/\/doi.org\/10.1210\/jc.2009-2575.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1841_CR53","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/imj.15774","volume":"52","author":"M Bonnichsen","year":"2022","unstructured":"Bonnichsen M, Stoklosa T, Bowen D, Majumdar A. Safety first, a harmful interaction between rivaroxaban and berberine. Intern Med J. 2022;52(5):887\u20138. https:\/\/doi.org\/10.1111\/imj.15774.","journal-title":"Intern Med J"},{"issue":"10","key":"1841_CR54","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11883-021-00955-y","volume":"23","author":"AFG Cicero","year":"2021","unstructured":"Cicero AFG, Fogacci F, Stoian AP, Vrablik M, Al Rasadi K, Banach M, et al. Nutraceuticals in the management of dyslipidemia: which, when, and for whom? Could nutraceuticals help low-risk individuals with non-optimal lipid levels? Curr Atheroscler Rep. 2021;23(10):57. https:\/\/doi.org\/10.1007\/s11883-021-00955-y.","journal-title":"Curr Atheroscler Rep"},{"issue":"4","key":"1841_CR55","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/mol.0000000000000754","volume":"32","author":"A Sniderman","year":"2021","unstructured":"Sniderman A, Langlois M, Cobbaert C. Update on apolipoprotein B. Curr Opin Lipidol. 2021;32(4):226\u201330. https:\/\/doi.org\/10.1097\/mol.0000000000000754.","journal-title":"Curr Opin Lipidol"},{"issue":"9","key":"1841_CR56","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11883-021-00951-2","volume":"23","author":"D Rhainds","year":"2021","unstructured":"Rhainds D, Brodeur MR, Tardif J-C. Lipoprotein (a): when to measure and how to treat? Curr Atheroscler Rep. 2021;23(9):51. https:\/\/doi.org\/10.1007\/s11883-021-00951-2.","journal-title":"Curr Atheroscler Rep"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01841-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01841-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01841-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T11:34:37Z","timestamp":1680780877000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01841-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1841"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01841-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.06.20.22276676","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,21]]},"assertion":[{"value":"31 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was not funded.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethics approval was not required as this is a review of completed studies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets supporting the conclusions of this article are included within the article and its additional files.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Conceptualization: JVZ and JEB. Data curation: XH and JVZ. Project administration: JVZ and JEB. Resources: JVZ. Supervision: JVZ. Validation: JVZ. Visualization: XH. Formal analysis: XH and JVZ. Writing\u2014original draft: JEB and XH. Writing\u2014review & editing: All authors.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' information"}}]}}